CGTN: UK Regulator Criticized for 'Act of Censorship' by Banning CGTN
10.3.2021 16:24:00 EET | Business Wire | Press release
Britain's communications regulator Ofcom has been criticized for its decision to ban and fine China Global Television Network (CGTN) for political reasons.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005537/en/
CGTN headquarters building in Beijing. /CFP
A group of journalists, filmmakers and artists recently challenged Ofcom's "act of censorship" in an open letter published by the No Cold War campaign and the Morning Star.
"The decision by Ofcom to remove the broadcasting license of CGTN is an act of censorship which is not in the interests of Britain and its people," the open letter said, calling the move an "attack on free speech."
Ofcom revoked the license of CGTN to broadcast in the UK in early February on the grounds of its ultimate control and its political attributes. Beijing slammed the move as political repression against Chinese media.
In their letter, the signatories questioned Ofcom's justification for banning CGTN.
"Ofcom's justification for taking CGTN off air is that any holder of a broadcasting license in Britain must not be controlled by political bodies. However, this law is only selectively applied. Numerous private and state channels have clear political agendas or control – the BBC itself, for example, which had its staff vetted by MI5, has not had its broadcasting license revoked," it said.
The letter urged Ofcom to reverse its decision and reinstate CGTN's license.
CGTN committed to balanced reporting
A spokesperson for CGTN on Tuesday called on the British regulator to calmly listen to the opinions expressed in the letter and end its political crackdown on Chinese media.
The spokesperson said that as an international news channel, CGTN is committed to providing "accurate, timely and objective news and information with diverse and balanced views" for its global audiences.
"China is increasingly connected and engaged with the rest of the world including the UK," the spokesperson said in a statement. "It is our responsibility to present Chinese viewpoints and perspectives in our news reporting, which is what our viewers expect and is also in the interest of the public."
'The world should be able to hear China's voice'
In a separate statement on Tuesday, CGTN said it is disappointed with and firmly opposes Ofcom's latest sanction decisions and adjudications against it.
Ofcom on Monday fined CGTN 225,000 British pounds (about $310,933) for "breaching rules on fairness, privacy and due impartiality" just weeks after it stripped the network of its right to air in Britain.
"CGTN believes its coverage of the 2019 violent protests in the Hong Kong Special Administrative Region was fair, truthful and duly impartial," the statement said.
"As a news outlet from China, CGTN made it possible for global audiences to see and hear a more complete picture of events in Hong Kong by reporting on the voices opposing violence and destruction," it stressed. "The fact that CGTN has been sanctioned by Ofcom for its objective coverage of the event is unjust."
"It is in the public interest that the world should be able to hear China's voice and perspective and see the true picture more clearly," it added.
At a regular press briefing on Tuesday, Chinese Foreign Ministry spokesperson Zhao Lijian urged Ofcom and certain individuals to immediately cease engaging in political manipulation and correct their mistakes, slamming the move as "blatant political oppression."
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005537/en/
Contact information
Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
